The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses

Clinical and Experimental Immunology

Volumn 173, Issue 1, 2013, Pages 8-17

  Modi, S ^a   Soejima, M ^a   Levesque, M C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Anti citrullinated protein autoantibodies; Biologic therapy; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BCL2 RELATED PROTEIN A1; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HLA DRB1 ANTIGEN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 6; LEFLUNOMIDE; LYMPHOTOXIN; METHOTREXATE; MINOCYCLINE; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; STAT3 PROTEIN; TOCILIZUMAB; TOFACITINIB; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; BONE DESTRUCTION; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; MEMORY CELL; NONHUMAN; PANNUS; PERIODONTAL DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIGNAL TRANSDUCTION; SMOKING; SOMATIC MUTATION; UPREGULATION;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL THERAPY; HUMANS; INTERLEUKINS; MICE; MOLECULAR TARGETED THERAPY; PEPTIDES, CYCLIC; PHOSPHOPYRUVATE HYDRATASE;

EID: 84878805640     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12114     Document Type: Review

References (109)

1. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101:273-281.
2. Levesque MC, Zhou Z, Moreland LW. Anti-CCP testing for the diagnosis of rheumatoid arthritis and the quest for improved sensitivity and predictive value. Arthritis Rheum 2009; 60:2211-2215.
3. Schellekens GA, Visser H, de Jong BA etal. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43:155-163.
4. Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003; 62:870-874.
5. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30:1205-1213.
6. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003; 171:538-541.
7. Klareskog L, Ronnelid J, Lundberg K, Padyukov L, Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 2008; 26:651-675.
8. Verpoort KN, Papendrecht-van der Voort EA, van der Helm-van Mil AH etal. Association of smoking with the constitution of the anti-cyclic citrullinated peptide response in the absence of HLA-DRB1 shared epitope alleles. Arthritis Rheum 2007; 56:2913-2918.
9. Silman AJ, Newman J, MacGregor AJ. Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum 1996; 39:732-735.
10. Stolt P, Bengtsson C, Nordmark B etal. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 2003; 62:835-841.
11. Kallberg H, Ding B, Padyukov L etal. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis 2011; 70:508-511.
12. Saevarsdottir S, Wedren S, Seddighzadeh M etal. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 2011; 63:26-36.
13. Klareskog L, Stolt P, Lundberg K etal. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54:38-46.
14. Morgan AW, Thomson W, Martin SG etal. Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population. Arthritis Rheum 2009; 60:2565-2576.
15. Mahdi H, Fisher BA, Kallberg H etal. Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet 2009; 41:1319-1324.
16. Wegner N, Lundberg K, Kinloch A etal. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 2010; 233:34-54.
17. Sokolove J, Zhao X, Chandra PE, Robinson WH. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcgamma receptor. Arthritis Rheum 2011; 63:53-62.
18. Clavel C, Nogueira L, Laurent L etal. Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum 2008; 58:678-688.
19. Zhao X, Okeke NL, Sharpe O etal. Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther 2008; 10:R94.
20. Burkhardt H, Sehnert B, Bockermann R, Engstrom A, Kalden JR, Holmdahl R. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol 2005; 35:1643-1652.
21. Uysal H, Bockermann R, Nandakumar KS etal. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med 2009; 206:449-462.
22. Bang H, Egerer K, Gauliard A etal. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007; 56:2503-2511.
23. Kinloch A, Lundberg K, Wait R etal. Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis. Arthritis Rheum 2008; 58:2287-2295.
24. Wegner N, Wait R, Sroka A etal. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and alpha-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum 2010; 62:2662-72.
25. Cantaert T, De Rycke L, Bongartz T etal. Citrullinated proteins in rheumatoid arthritis: crucial ... but not sufficient! Arthritis Rheum 2006; 54:3381-3389.
26. Kuhn KA, Kulik L, Tomooka B etal. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006; 116:961-973.
27. Petkova SB, Konstantinov KN, Sproule TJ, Lyons BL, Awwami MA, Roopenian DC. Human antibodies induce arthritis in mice deficient in the low-affinity inhibitory IgG receptor Fc gamma RIIB. J Exp Med 2006; 203:275-280.
28. Hill JA, Bell DA, Brintnell W etal. The arthritogenicity of human anti-citrullinated peptide antibodies in rheumatoid arthritis (RA). J Exp Med 2008; 205:967-979.
29. Hill JA, Bell DA, Brintnell W etal. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 2008; 205:967-979.
30. Kroot EJ, de Jong BA, van Leeuwen MA etal. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000; 43:1831-1835.
31. Meyer O, Labarre C, Dougados M etal. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003; 62:120-126.
32. Genovese MC, Kaine JL, Lowenstein MB etal. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58:2652-2661.
33. Cambridge G, Leandro MJ, Edwards JC etal. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48:2146-2154.
34. Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, Tak PP. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56:772-778.
35. Walsh CAE, Fearon U, FitzGerald O, Veale DJ, Bresnihan B. Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy. Clin Exp Rheumatol 2008; 26:656-658.
36. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370:1861-1874.
37. Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. Expert Opin Pharmacother 2007; 8:2089-2107.
38. Mikuls TR, O'Dell JR, Stoner JA etal. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 2004; 50:3776-3782.
39. Alessandri C, Bombardieri M, Papa N etal. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004; 63:1218-1221.
40. Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004; 6:R264-272.
41. Caramaschi P, Biasi D, Tonolli E etal. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int 2005; 26:58-62.
42. De Rycke L, Verhelst X, Kruithof E etal. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 2005; 64:299-302.
43. Atzeni F, Sarzi-Puttini P, Dell'Acqua D etal. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 2006; 8:R3.
44. Chen HA, Lin KC, Chen CH etal. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65:35-39.
45. Cuchacovich M, Catalan D, Wainstein E etal. Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis. Clin Exp Rheumatol 2008; 26:1067-1073.
46. Vis M, Bos WH, Wolbink G etal. IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis. J Rheumatol 2008; 35:425-428.
47. Bacquet-Deschryver H, Jouen F, Quillard M etal. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol 2008; 28:445-455.
48. Bos WH, Bartelds GM, Wolbink GJ etal. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol 2008; 35:1972-1977.
49. Bruns A, Nicaise-Roland P, Hayem G etal. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Joint Bone Spine 2009; 76:248-253.
50. Roll P, Muhammad K, Schumann M etal. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum 2011; 63:1255-1264.
51. Muhammad K, Roll P, Seibold T etal. Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells. Rheum Dis 2011; 70:1507-1510.
52. Edwards JC, Szczepanski L, Szechinski J etal. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572-2581.
53. Emery P, Fleischmann R, Filipowicz-Sosnowska A etal. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54:1390-1400.
54. Cohen SB, Emery P, Greenwald MW etal. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54:2793-2806.
55. Hoyer BF, Moser K, Hauser AE etal. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004; 199:1577-1584.
56. Schroder AE, Greiner A, Seyfert C, Berek C. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci USA 1996; 93:221-225.
57. Radbruch A, Muehlinghaus G, Luger EO etal. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006; 6:741-750.
58. Reparon-Schuijt CC, van Esch WJ, van Kooten C etal. Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum 2001; 44:41-47.
59. Reparon-Schuijt CC, van Esch WJ, van Kooten C, Levarht EW, Breedveld FC, Verweij CL. Functional analysis of rheumatoid factor-producing B cells from the synovial fluid of rheumatoid arthritis patients. Arthritis Rheum 1998; 41:2211-2220.
60. Leandro MJ, Cooper N, Cambridge G, Ehrenstein MR, Edwards JCW. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology 2007; 46:29-36.
61. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JCW. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:613-620.
62. Anolik JH, Ravikumar R, Barnard J etal. Anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 2008; 180:688-692.
63. Cassese G, Arce S, Hauser AE etal. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol 2003; 171:1684-1690.
64. Quirke A-M, Fisher BAC, Kinloch AJ, Venables PJ. Citrullination of autoantigens: upstream of TNF-α in the the pathogenesis of rheumatoid arthritis. FEBS Lett 2011; 585:3681-3688.
65. Souto-Carneiro MM, Mahadevan V, Takada K etal. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther 2009; 11:R84.
66. Fekete A, Soos L, Szekanecz Z etal. Disturbances in B- and T-cell homeostasis in rheumatoid arthritis: suggested relationships with antigen-driven immune responses. J Autoimmun 2007; 29:154-163.
67. Bellatin MF, Han M, Fallena M etal. Production of autoantibodies against citrullinated antigens/peptides by human B cells. J Immunol 2012; 188:3542-3550.
68. Catalab D, Aravena O, Sabugo F etal. B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy. Arthritis Res Ther 2010; 12:R68.
69. Mongini PK, Tolani S, Fattah RJ, Inman JK. Antigen receptor triggered upregulation of CD86 and CD80 in human B cells: augmenting role of the CD21/CD19 co-stimulatory complex and IL-4. Cell Immunol 2002; 216:50-64.
70. Good KL, Avery DT, Tangye SG. Resting human memory B cells are intrinsically programmed for enhanced survival and responsiveness to diverse stimuli compared to naive B cells. J Immunol 2009; 182:890-901.
71. Chen JY, Wang CM, Ma CC etal. Transmembrane polymorphism in FcgammaRIIb (FCGR2B) is associated with the production of anti-cyclic citrullinated peptide autoantibodies in taiwanese RA. Genes Immun 2008; 9:680-688.
72. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 2005; 64:403-407.
73. De Bandt M, Sibilis J, Le Loet X etal. Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005; 7:R545-551.
74. Karampetsou MP, Andonopoulos AP, Liossis SNC. Treatment of with TNFa blockers induces phenotype and functional aberrations in peripheral B cells. Clin Immunol 2011; 140:8-17.
75. Xu Y, Harder KW, Huntington ND, Hibbs ML, Tarlinton DM. Lyn tyrosine kinase: accentuating the positive and negative. Immunity 2005; 22:9-18.
76. Puel A, Cypowyj S, Bustamante J etal. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011; 332:65-68.
77. Doreau A, Belot A, Bastid J etal. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009; 10:778-785.
78. Hueber W, Patel DD, Dryja T etal. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2:52ra72.
79. Genovese MC, Van den Bosch F, Roberson SA etal. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010; 62:929-939.
80. van Hamburg JP, Asmawidjaja PS, Davelaar N etal. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 2011; 63:73-83.
81. Chen Z, Laurence A, Kanno Y etal. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci USA 2006; 103:8137-8142.
82. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24:179-189.
83. Toubi E, Kessel A, Slobodin G etal. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66:818-820.
84. Groom JR, Fletcher CA, Walters SN etal. BAFF and MyD88 signals promote a lupus-like disease independent of T cells. J Exp Med 2007; 204:1959-1971.
85. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44:1313-1319.
86. Roschke V, Sosnovtseva S, Ward CD etal. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002; 169:4314-4321.
87. Tan S-M, Xu D, Roschke V etal. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003; 48:982-992.
88. Bosello S, Youinou P, Daridon C etal. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 2008; 35:1256-1264.
89. Vallerskog T, Heimburger M, Gunnarsson I etal. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006; 8:R167.
90. Wilker PR, Kohyama M, Sandau MM etal. Transcription factor Mef2c is required for B cell proliferation and survival after antigen receptor stimulation. Nat Immunol 2008; 9:603-612.
91. Iwamoto S, Iwai S, Tsujiyama K etal. TNF-alpha drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses. J Immunol 2007; 179:1449-1457.
92. Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 2008; 205:2491-2497.
93. Ohata J, Zvaifler NJ, Nishio M etal. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005; 174:864-870.
94. Alsaleh G, Messer L, Semaan N etal. BAFF synthesis by rheumatoid synoviocytes is positively controlled by alpha5beta1 integrin stimulation and is negatively regulated by tumor necrosis factor alpha and Toll-like receptor ligands. Arthritis Rheum 2007; 56:3202-3214.
95. Niesner U, Albrecht I, Janke M etal. Autoregulation of Th1-mediated inflammation by twist1. J Exp Med 2008; 205:1889-1901.
96. Ying H, Yang L, Qiao G etal. Cutting edge: CTLA-4-B7 interaction suppresses Th17 cell differentiation. J Immunol 2010; 185:1375-1378.
97. Tanaka Y, Yamaoka K. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Mod Rheumatol Published online on December 2012. doi: 10.1007/s10165-012-0799-2.
98. Tanaka Y, Maeshima Y, Yamaoka K. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis. Ann Rheum Dis 2012; 71 (Suppl. 2):i70-74.
99. Bax M, van Heemst J, Huizinga TW, Toes RE. Genetics of rheumatoid arthritis: what have we learned? Immunogenetics 2011; 63:459-466.
100. Huizinga TW, Amos CI, van der Helm-van MA etal. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005; 52:3433-3438.
101. Kallberg H, Padyukov L, Plenge RM etal. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007; 80:867-875.
102. Kokkonen H, Johansson M, Innala L, Jidell E, Rantapaa-Dahlqvist S. The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden. Arthritis Res Ther 2007; 9:R56.
103. Linn-Rasker SP, van der Helm-van MA, van Gaalen FA etal. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 2006; 65:366-371.
104. Padyukov L, Seielstad M, Ong RT etal. A genomewide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 2011; 70:259-265.
105. Aringer M, Smolen JS. Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Res Ther 2003; 5:172-177.
106. Chatzidakis I, Mamalaki C. T cells as sources and targets of TNF: implications for immunity and autoimmunity. Curr Dir Autoimmun 2010; 11:105-118.
107. Zucali JR, Elfenbein GJ, Barth KC etal. Effects of human interleukin 1 and human tumor necrosis factor on human T lymphocyte colony formation. J Clin Invest 1987; 80:772-777.
108. Kormelink TG, Tekstra J, Thurlings RM etal. Decrease in immunoglobulin free light chains in patient swith rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity. Ann Rheum Dis 2010; 69:2137-2144.
109. Rosengren S, Wei N, Kulunian KC, Zvaifler NJ, Kavanugh A, Boyle DL. Elevated autoantibody content in rheumatoid arthritis synovial with lymphoid aggregates and the effect of rituximab. Arthritis Res Ther 2008; 10:R105.